Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCEZ7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The award, issued on December 3, 2025, with an ultimate completion date of December 24, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $500 million ceiling value extending through December 31, 2036.
The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying comprehensive pharmaceutical products and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's contract structure includes a 30-month base period with three 30-month option periods, positioning the company as a critical pharmaceutical supplier for Department of Defense healthcare operations. The company's established performance on numerous prior delivery orders for diverse pharmaceutical products, including specialty biologics, oncology treatments, vaccines, and emergency medications, demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCEZ7?
SPE2DR26FCEZ7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FCEZ7 worth?
The government has obligated $16,584 on SPE2DR26FCEZ7.
Is contract SPE2DR26FCEZ7 an order under another contract?
Yes. SPE2DR26FCEZ7 is a delivery order under SPE2DR25D9130, an indefinite delivery contract.
Was contract SPE2DR26FCEZ7 competed?
The extent of competition for SPE2DR26FCEZ7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award